Article info

PDF

Extended report
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis

Authors

  1. Correspondence to Dr Gerd R Burmester, Director, Department of Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Free University, and Humboldt University Berlin Charitéplatz 1, Berlin 10117, Germany; Gerd.Burmester{at}charite.de
View Full Text

Citation

Burmester GR, McInnes IB, Kremer J on behalf of the EARTH EXPLORER 1 study investigators, et al
A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis

Publication history

  • Received September 30, 2016
  • Revised December 9, 2016
  • Accepted January 16, 2017
  • First published February 17, 2017.
Online issue publication 
May 13, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.